Neumann, Jan; Ziegler, Kira; Gelleri, Marton et al.
Nanoscale distribution of TLR4 on primary human macrophages stimulated with LPS and ATINANOSCALE. Bd. 11. H. 19. 2019 S. 9769-9779
Jungmann, F.; Kuhn, S.; Tsaur, I. et al.
Natural language processing in radiology Neither trivial nor impossibleRADIOLOGE. Bd. 59. H. 9. 2019 S. 828-832
Sasca, Daniel; Szybinski, Jakub; Schueler, Andrea et al.
NCAM1 (CD56) promotes leukemogenesis and confers drug resistance in AMLBLOOD. Bd. 133. H. 21. 2019 S. 2305-2319
Gulati, Shraddha; Emmanuel, Andrew; Pavlidis, Polychronis et al.
NEAR FOCUS NBI CLASSIFICATION OF VILLOUS ATROPHY IN SUSPECTED COELIAC DISEASE: INTERNATIONAL DEVELOPMENT AND VALIDATIONGASTROINTESTINAL ENDOSCOPY. Bd. 89. H. 6. 2019 S. AB49-AB49
Gulati, Shraddha; Emmanuel, Andrew; Patel, Mehul et al.
NEAR-FOCUS NBI CLASSIFICATION OF VILLOUS ATROPHY IN SUSPECTED COELIAC DISEASE: INTERNATIONAL DEVELOPMENT AND VALIDATIONGUT. Bd. 68. 2019 S. A11-A12
Pischedda, F.; Szczurkowska, J.; Pinto, B. et al.
NEGR1 and FGFR2 cooperatively regulate cortical development and core behaviors related to autism spectrum disorders in miceJOURNAL OF NEUROCHEMISTRY. Bd. 150. 2019 S. 193-193
Pena, Loren; Barohn, Richard J.; Dimachkie, Mazen M. et al.
NEO1 and NEO-EXT studies: Long-term safety of repeat avalglucosidase alfa dosing for 4.5 years in late-onset Pompe disease patientsMOLECULAR GENETICS AND METABOLISM. Bd. 126. H. 2. 2019 S. S115-S116
Dimachkie, Mazen M.; Barohn, Richard J.; Kishnani, Priya S. et al.
NEO1 and NEO-EXT Studies: Long-Term Safety of Repeat Avalglucosidase Alfa Dosing for 4.5 Years in Patients With Late-Onset Pompe DiseaseNEUROLOGY. Bd. 92. H. 15. 2019
Schoser, B.; Barohn, R.; Dimachkie, M. et al.
NEO1 and NEO-EXT studies: pharmacodynamic and exploratory biomarker assessments following repeat avalglucosidase alfa dosing for up to 4.5 years in patients with late-onset Pompe diseaseEUROPEAN JOURNAL OF NEUROLOGY. Bd. 26. 2019 S. 326-326
Dimachkie, Mazen; Barohn, Richard; Kishnani, Priya et al.
NEO1 AND NEO-EXT STUDIES: PHARMACODYNAMIC/EXPLORATORY BIOMARKER AND SAFETY ASSESSMENTS FOLLOWING REPEAT AVALGLUCOSIDASE ALFA DOSING FOR UP TO 4.5 YEARS IN PATIENTS WITH LATE-ONSET POMPE DISEASEMUSCLE & NERVE. Bd. 60. 2019 S. S48-S49